Sino Biopharmaceutical Limited (FRA:SMZ1)

Sino Biopharmaceutical Statistics

Total Valuation

FRA:SMZ1 has a market cap or net worth of EUR 15.94 billion. The enterprise value is 16.48 billion.

Market Cap	15.94B
Enterprise Value	16.48B

Important Dates

The next estimated earnings date is Monday, November 17, 2025.

Earnings Date	Nov 17, 2025
Ex-Dividend Date	Aug 29, 2025

Share Statistics

Current Share Class	17.88B
Shares Outstanding	n/a
Shares Change (YoY)	-2.10%
Shares Change (QoQ)	-0.85%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	8.80B

Valuation Ratios

The trailing PE ratio is 34.64 and the forward PE ratio is 29.14.

PE Ratio	34.64
Forward PE	29.14
PS Ratio	4.39
PB Ratio	2.93
P/TBV Ratio	4.43
P/FCF Ratio	22.83
P/OCF Ratio	20.02
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.76, with an EV/FCF ratio of 23.61.

EV / Earnings	35.82
EV / Sales	4.49
EV / EBITDA	19.76
EV / EBIT	24.05
EV / FCF	23.61

Financial Position

The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.26.

Current Ratio	1.36
Quick Ratio	1.14
Debt / Equity	0.26
Debt / EBITDA	1.71
Debt / FCF	2.04
Interest Coverage	21.69

Financial Efficiency

Return on equity (ROE) is 15.40% and return on invested capital (ROIC) is 6.55%.

Return on Equity (ROE)	15.40%
Return on Assets (ROA)	5.07%
Return on Invested Capital (ROIC)	6.55%
Return on Capital Employed (ROCE)	11.47%
Revenue Per Employee	157,581
Profits Per Employee	19,958
Employee Count	24,379
Asset Turnover	0.43
Inventory Turnover	2.83

Taxes

In the past 12 months, FRA:SMZ1 has paid 102.24 million in taxes.

Income Tax	102.24M
Effective Tax Rate	11.27%

Stock Price Statistics

The stock price has increased by +108.39% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+108.39%
50-Day Moving Average	0.86
200-Day Moving Average	0.55
Relative Strength Index (RSI)	45.07
Average Volume (20 Days)	17,150

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:SMZ1 had revenue of EUR 3.63 billion and earned 460.14 million in profits. Earnings per share was 0.03.

Revenue	3.63B
Gross Profit	2.97B
Operating Income	682.26M
Pretax Income	906.96M
Net Income	460.14M
EBITDA	817.79M
EBIT	682.26M
Earnings Per Share (EPS)	0.03

Balance Sheet

The company has 2.36 billion in cash and 1.42 billion in debt, giving a net cash position of 935.13 million.

Cash & Cash Equivalents	2.36B
Total Debt	1.42B
Net Cash	935.13M
Net Cash Per Share	n/a
Equity (Book Value)	5.44B
Book Value Per Share	0.22
Working Capital	1.07B

Cash Flow

In the last 12 months, operating cash flow was 796.02 million and capital expenditures -97.88 million, giving a free cash flow of 698.15 million.

Operating Cash Flow	796.02M
Capital Expenditures	-97.88M
Free Cash Flow	698.15M
FCF Per Share	n/a

Margins

Gross margin is 81.77%, with operating and profit margins of 18.78% and 12.67%.

Gross Margin	81.77%
Operating Margin	18.78%
Pretax Margin	24.96%
Profit Margin	12.67%
EBITDA Margin	22.51%
EBIT Margin	18.78%
FCF Margin	19.22%

Dividends & Yields

This stock pays an annual dividend of 0.01, which amounts to a dividend yield of 1.15%.

Dividend Per Share	0.01
Dividend Yield	1.15%
Dividend Growth (YoY)	40.37%
Years of Dividend Growth	n/a
Payout Ratio	47.69%
Buyback Yield	2.10%
Shareholder Yield	3.24%
Earnings Yield	2.89%
FCF Yield	4.38%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on July 20, 2020. It was a forward split with a ratio of 1.5.

Last Split Date	Jul 20, 2020
Split Type	Forward
Split Ratio	1.5

Scores

FRA:SMZ1 has an Altman Z-Score of 2.54 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.54
Piotroski F-Score	7